Topic: peripheral artery disease
2015 Fierce 15 company Shockwave Medical is going public, filing for a $75 million IPO on the Nasdaq with the ticker symbol SWAV.
PQ Bypass gathered $60 million in financing to move its minimally invasive tech for circumventing long blockages in leg arteries caused by PAD.
Medtronic’s final, five-year study data showed the durability of its drug-coated angioplasty balloon in peripheral artery disease.
On the back of a positive head-to-head trial, the FDA approved Boston Scientific’s drug-eluting stent for peripheral artery disease.
Reva netted a CE mark for the first drug-eluting bioresorbable scaffold in lower-leg peripheral artery disease, and the company’s first in the space.
Pluristem and Thermo Fisher will collaborate to scale up manufacturing of regenerative medicines, to build an industry capable of millions of doses.
Fresenius signed a $150 million global commercialization deal with Humacyte for its regenerative blood vessel implant and bought 19% of the company.
Abbott is paying $25 million upfront and committing to up to $67 million in development milestones to add the device to its vascular disease pipeline.
Shockwave's new financing will expand commercialization of its ultrasound balloon treatment for calcified artery disease and boost R&D.
A 20-patient study showed its ultrasound PAD balloon was effective in patients with arterial blockage below the knee.